News

The companies will assess AdAlta’s CXCR4 inhibiting i-bodies as cancer therapeutics, using GPCR’s combination inhibition technique. AdAlta owns an i-bodies panel that inhibit CXCR4 signalling in different ways.

The company is seeking regulatory approval for SIS-101-ADO to treat Autosomal Dominant Osteopetrosis Type 2 (ADO2) patients. CSSi LifeSciences will be responsible for coordinating the regulatory process that

The CRISPR-based gene therapy has been indicated to treat Shiga-toxin producing bacterial infection to prevent hemolytic uremic syndrome (HUS). It has been designed to target Shiga toxins from

The injection (abbreviated as relma-cel ) has been approved to treat adult patients with follicular lymphoma that relapses or is refractory in 24 months of second-line or above

Discovered and developed by Lilly, Cyramza has been approved for the treatment of HCC patients with an alpha fetoprotein of ≥400 ng/mL and who have received treatment with

Oxlumo, which is administered through subcutaneous injection, has now been indicated to treat PH1 to reduce the levels of urinary oxalate (UOx) and plasma oxalate (POx) in paediatric

The decision to not submit the EUA application was made after receiving feedback from the FDA. Last month, the company submitted a request to FDA for a pre-EUA

The partnership will particularly focus on identifying composite biomarkers, which integrate several biological entities into a single readout. This identification will help guide therapeutic decision making. Gastroesophageal cancer

The company was created after the acquisition of Alexion Pharmaceuticals by AstraZeneca last year. The aim of the acquisition is to expedite the expansion of Alexion into genomic